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Resistance to every family of clinically used antibi-
otics has emerged, and there is apressing need toex-
plore unique antibacterial targets. Wall teichoic acids
(WTAs) are anionic polymers that coat the cell walls of
manyGram-positive bacteria. BecauseWTAsplay an
essential role in Staphylococcus aureus colonization
and infection, the enzymes involved in WTA biosyn-
thesis are proposed to be targets for antibiotic devel-
opment. To facilitate the discovery of WTA inhibitors,
we have reconstituted the intracellular steps of S. au-
reusWTA biosynthesis. We show that two intracellu-
lar steps in the biosynthetic pathway are different
from what was proposed. The work reported here
lays the foundation for the discovery and character-
ization of inhibitors of WTA biosynthetic enzymes to
assess their potential for treating bacterial infections.INTRODUCTION
Wall teichoic acids (WTAs) are anionic polymers ofGram-positive
bacteria that are covalently attached to the peptidoglycan chains
(Figure 1) (Neuhaus and Baddiley, 2003). In Staphylococcus au-
reus,WTAshavebeenshown toplay essential roles in host-tissue
colonization and the spread of infection (Weidenmaier et al.,
2004, 2005). They contribute to bacterial resistance to human
lysozyme, which is a component of the innate immune response
that destroys bacteria by hydrolyzing the peptidoglycan layers
(Bera et al., 2007). WTAs have also been shown to play a role in
biofilm formation (Gross et al., 2001; Vinogradov et al., 2006;
Walter et al., 2007). Therefore, inhibitors of the WTA biosynthetic
pathwaymaybeuseful for treating infections causedbyS. aureus
andotherGram-positive pathogens (Weidenmaier et al., 2003). In
order to identify andcharacterize such inhibitors, it is important to
understand the steps involved in WTA biosynthesis. Although
S. aureus strains are known to make polyribitol phosphate (poly-
RboP) WTAs (Fiedler and Glaser, 1974; Harrington and Baddiley,
1985; Heckels et al., 1975; Yokoyama et al., 1986), the biosyn-
thetic pathway is not well characterized, and the proposed path-
way (Figure 2A) is largely based on studies done with B. subtilis
(Lazarevic et al., 2002; Qian et al., 2006; Ward, 1981).
WTAs consist of a disaccharide-based linkage unit and a re-
peating polyol-phosphate polymer such as polyglycerol phos-12 Chemistry & Biology 15, 12–21, January 2008 ª2008 Elsevier Ltdphate (polyGroP) or polyRboP (Neuhaus and Baddiley, 2003).
WTAs are synthesized on a diphospholipid carrier anchored in
the cytoplasmic membrane and are then translocated through
a two-component transporter to the outside of the cell, where
they are attached by a phosphodiester linkage to the C6 hydroxyl
of the N-acetyl muramic acid sugars of peptidoglycan (Figure 1)
(Neuhaus and Baddiley, 2003). The most common linkage unit,
found in all B. subtilis and S. aureus strains, is ManNAc-b-(1,4)-
GlcNAc-(GroP)n, where n is proposed to be 2 in B. subtilis W23
and 3 in S. aureus (Harrington and Baddiley, 1985; Yokoyama
et al., 1986). Common repeat units include polyGroP, found in
B. subtilis 168, and polyRboP, found in B. subtilis W23 as well
as S. aureus (Neuhaus and Baddiley, 2003; Yokoyama et al.,
1986). Functions have been established for most of the tag (for
teichoic acid glycerol) genes in B. subtilis 168 (Bhavsar et al.,
2005; Ginsberg et al., 2006; Qian et al., 2006; Schertzer et al.,
2005; Schertzer and Brown, 2003), and putative functions were
assigned to the tar (for teichoic acid ribitol) genes involved in pol-
yRboP-WTA biosynthesis based on sequence homology to the
tag genes (Lazarevic et al., 2002; Qian et al., 2006) (Figure 2A).
Thus, it was proposed that polyRboP-WTA biosynthesis starts
with the TarO-mediated transfer of GlcNAc to a membrane-an-
chored undecaprenyl carrier lipid. Consistent with this, an S. au-
reus SA113 strain in which tarO is disrupted does not express
WTAs (Weidenmaier et al., 2004). WTA biosynthesis was pro-
posed to continue with the TarA-mediated transfer of ManNAc
to the C4 hydroxyl of GlcNAc to form ManNAc-b-(1,4)-GlcNAc-
pp-undecaprenyl, whereupon TarB adds glycerol-3-phosphate
to the C4 hydroxyl of theManNAcmoiety (D’Elia et al., 2006; Laz-
arevic et al., 2002; Qian et al., 2006). The proposed functions of
TarA and TarB are thus identical to the established functions of
TagA and TagB (Ginsberg et al., 2006; Qian et al., 2006). After
the TarB step, the pathways for polyGroP- and polyRboP-WTA
biosynthesis diverge. Whereas TagF is a polymerase that adds
dozens of GroP units to the disaccharide-based linkage unit in
B. subtilis 168 (Schertzer et al., 2005; Schertzer and Brown,
2003), TarF is a putative primase. B. subtilis TarF was proposed
to add one GroP to the disaccharide linkage unit, whereas S. au-
reus TarF was proposed to add two GroPs (D’Elia et al., 2006;
Qian et al., 2006). (The tarO, tarA, tarB, and tarF genes found in
polyRboP-WTA-forming bacteria are sometimes annotated as
tagO, tagA, tagB, and tagF because of their similarity to the
genes involved polyGroP-WTA biosynthesis.) Two additional
gene products, a putative ribitol-5-phosphate primase, TarK,
and a putative RboP polymerase, TarL, are proposed to build
the poly-ribitol-phosphate polymer (D’Elia et al., 2006; LazarevicAll rights reserved
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source of the enzymes described below, the genes suggested
to be responsible for each step in polyRboP-WTA biosynthesis
are indicated in Figure 2A.
The pathway proposed in Figure 2A was recently questioned
by Qian et al. (2006), who carried out a genomic analysis of sev-
eral fully sequenced S. aureus strains. Their analysis shows that
the candidates for TarK and TarL, the two RboP transferases, are
very similar in all S. aureus strains. Because of the high sequence
homology between TarK and TarL, Qian et al. (2006) suggested
that both gene products may function as polymerases, and that
there may not be a distinct RboP primase and a distinct RboP
polymerase (Qian et al., 2006). Here, we report the in vitro recon-
stitution of the intracellular steps downstream of TarO in theWTA
biosynthetic pathway in S. aureus. In addition to TarD, TarI, and
TarJ, which supply the CDP-glycerol and CDP-ribitol substrates
(Badurina et al., 2003; Pereira and Brown, 2004), we show that
TarA, TarB, TarF, and TarL are required to convert the GlcNAc-
pp-lipid product of TarO to the full-length polyribitol polymer.
Based on our studies, we propose a revised WTA biosynthetic
pathway for S. aureus in which the number of GroP units added
by TarF is altered and the proposed polyRboP primase (TarK) is
omitted (compare Figures 2A and 2B). This work clarifies the bio-
synthetic pathway in S. aureus, and it may also enable efforts to
discover and characterize WTA inhibitors that can be used to
assess whether the WTA pathway is a target for therapeutic
intervention.
RESULTS
In Vitro Reconstitution of S. aureus TarA
TheSAOUHSC_00640 gene, encoding SA640, a putative N-ace-
tylmannosaminyl transferase with 55% similarity to B. subtilis
168 TagA, was PCR amplified from S. aureus NCTC8325 geno-
Figure 1. Wall Teichoic Acid Structure
Schematic showing the first intracellular step in polyribitol phosphate wall tei-
choic acid (WTA) biosynthesis and the final WTA product attached to a frag-
ment of nascent S. aureus peptidoglycan. As reported in this manuscript,
n = 2 GroP units for S. aureus WTAs. X and Y on the ribitol hydroxyls in the
schematic indicate S. aureus tailoring modifications such as the attachment
of GlcNAc or D-alanine (Ward, 1981).Chemistry & Biologymic DNA. The PCR product was cloned into a pET24b(+) vector
for expression as a C-terminal hexa-His-tagged protein. The
protein was overexpressed in E. coli strain Rosetta2(DE3)pLysS
and was purified by Ni2+-affinity chromatography. SA640 is pro-
posed to transfer ManNAc from UDP-ManNAc to a GlcNAc-
pp-undecaprenyl carrier lipid. We have previously shown that
B. subtilis TagA accepts GlcNAc-pp-lipid substrates containing
farnesyl chains and is functional in the absence of membranes
(Zhang et al., 2006). Therefore, we incubated SA640 with UDP-
ManNAc and the synthetic GlcNAc-pp-farnesyl acceptor sub-
strate under the same conditions used to characterize B. subtilis
TagA (Zhang et al., 2006). We have previously described the syn-
thesis of these substrates (Ginsberg et al., 2006). HPLC analysis
(Figures 3A and 3B) of the reaction showed the disappearance of
UDP-ManNAc and the concomitant appearance of a UDP peak.
The reaction product was found to have a retention time of 11.7
min, identical to an authentic standard generated in the TagA re-
action and previously characterized byMS and 1H-NMR (Figures
3C and 3D) (Ginsberg et al., 2006; Zhang et al., 2006). The reac-
tion was quenched, and the lipid-linked product was separated
from other reaction components over a Phenomenex Strata
C18-E column and was analyzed by MS. The product was found
to have a mass of 787.3, consistent with compound 2b (calc’d
m/z: 787.2819). These experiments verify that SA640 encodes
the UDP-ManNAc transferase TarA, which makes compound 2
(Figure 2B).
In Vitro Reconstitution of S. aureus TarB
The SAOUHSC_00643 gene, encoding SA643, a putative glyc-
erol phosphotransferase with 53% homology to TagB from B.
subtilis 168, was PCR amplified fromS. aureusNCTC8325 geno-
mic DNA. The gene was cloned into a pET24b(+) vector, overex-
pressed in E. coli strain Rosetta2(DE3)pLysS as a C-terminal
hexa-His-tagged protein, and purified via Ni2+-affinity chroma-
tography. SA643 is proposed to transfer glycerol-3-phosphate
from CDP-glycerol to the disaccharide-lipid product of TarA.
Therefore, we examined its ability to transfer GroP to compound
2b, which we have previously shown to be a substrate for
B. subtilis 168 TagB (Ginsberg et al., 2006). Reactions containing
ManNAc-b-(1,4)-GlcNAc-pp-lipid (the TarA product) and CDP-
glycerol were monitored by HPLC. The CDP-glycerol peak
(retention time of 7.56 min) decreased in intensity, and a new
peak, corresponding to CMP (retention time of 3.85 min), ap-
peared. Under the same conditions, SA643 was unable to utilize
CDP-ribitol as a substrate, as judged by the stability of the CDP-
ribitol peak (retention time of 7.54min) in the HPLC trace (Figures
4A–4C). Using radiolabeled [14C]-CDP-glycerol, we could also
monitor the SA643 reaction by polyacrylamide gel electrophore-
sis followed by phosphorimaging analysis. The gel (Figure 4D)
shows a new spot in the enzyme reaction that is not present in
the heat-treated control. This new spot has the same mobility
as the authentic product generated by reacting [14C]-CDP-glyc-
erol and compound 2bwith B. subtilis 168 TagB. The lipid-linked
product from a TarB reaction utilizing nonradioactive substrates
was purified over a C18 column and subjected to MS analysis.
The purified product has a mass of 941.3, consistent with struc-
ture 3b (calc’d m/z: 941.2851). These results verify that SA643
encodes the glycerol phosphate transferase TarB, which makes
compound 3 (Figure 2B).15, 12–21, January 2008 ª2008 Elsevier Ltd All rights reserved 13
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SAOUHSC_00223, encoding SA223, which is 67% similar to
B. subtilisW23TarF,wascloned fromS.aureusNCTC8325geno-
mic DNA, overexpressed in E. coli, and purified over a Ni2+-affin-
ity column. S. aureus TarF is proposed to transfer two units of
glycerol-3-phosphate from CDP-glycerol to compound 3. To
assess the function of SA223, we incubated the purified
enzyme with purified [14C]-glycerol-3-phosphate-ManNAc-b-
(1,4)-GlcNAc-pp-lipid (3b) and either [14C]-CDP-glycerol or
CDP-ribitol. Reactions were monitored by polyacrylamide gel
electrophoresis (Figure 5A). A lower spot appeared in the [14C]-
CDP-glycerol reaction that was not present in the heat-treated
controls or in the CDP-ribitol reaction. The new spot migrates14 Chemistry & Biology 15, 12–21, January 2008 ª2008 Elsevier Ltdfaster than the starting material, but it was found to depend on
the presence of both [14C]-CDP-glycerol and the TarB product.
Therefore, we carried out an enzymatic reaction with nonradiola-
beled 3b andCDP-glycerol, purified the lipid-linkedmaterial over
a C18 column, and subjected the material to MS analysis. The
product was found to have an m/z of 1095.3 (calc’d m/z:
1095.2882), which corresponds to the addition of one glycerol-
3-phosphate unit to compound 3b to form compound 4b. No
products containing additional GroP units were observed un-
der any conditions. We have concluded that SA223 is TarF,
and that TarF in S. aureus NCTC8325 functions to add one unit
of glycerol-3-phosphate to compound 3 to produce (glycerol-
3-phosphate)2-ManNAc-b-(1,4)-GlcNAc-pp-lipid (compound 4)Figure 2. Proposed and Reconstituted WTA Biosynthetic Pathway in S. aureus
(A) The proposed polyribitol-phosphateWTA biosynthetic pathway. The S. aureusNCTC8325 gene encoding each putative protein is shown by its locus tag num-
ber in the block arrow next to the enzyme name.
(B) The revised polyribitol-phosphateWTA pathway in S. aureus based on in vitro reconstitution. R = undecaprenyl (compounds 1a–5a) for the natural lipid carrier
or farnesyl (compounds 1b–5b) for the alternative lipid used in the in vitro experiments. Differences between the proposed and reconstituted pathways are high-
lighted by larger bold text.All rights reserved
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S. aureus strains are different, we propose that S. aureus TarF,
like B. subtilisW23 TarF, transfers a single GroP unit.
In Vitro Reconstitution of the Ribitolphosphotransferase
Polymerase, TarL
All sequencedS. aureus strains contain twogenes that share high
homology to one another and to the B. subtilisW23 tarL and tarK
genes (Qian et al., 2006). In B. subtilisW23, TarK is proposed to
be a primase that adds one or a few units of ribitol-5-phosphate,
whereas TarL is proposed to be a ribitol-5-phosphate polymer-
ase that adds many RboP units (D’Elia et al., 2006; Lazarevic
et al., 2002; Qian et al., 2006). Qian et al. (2006) have suggested
that the two candidate genes for TarK and TarL in S. aureus
may actually be duplicates of one another and may have similar
functions. Toassess the functionsof the twoputativeRboP trans-
ferases in S. aureus NCTC8325 (SA222 and SA227), we cloned
the genes for these proteins from genomic DNA into pET24b(+),
expressed them in E. coli, and purified the expressed proteins
by Ni2+-affinity column chromatagraphy. SA222 was incubated
with [14C]-4b and CDP-ribitol, and the reaction mixture was
analyzed by polyacrylamide gel electrophoresis; however, no
change in the mobility of the radiolabeled starting material was
observed. Similarly, no change was observed when CDP-glyc-
erol was included in the reaction. Concerned that a product
involving the addition of a single RboP unit might not separate
from the starting material under the gel-electrophoresis condi-
tions used, we analyzed a set of nonradioactive reactions by
HPLC. SA222 was separately incubated with compound 3b
and compound 4b and either CDP-ribitol or CDP-glycerol, but
we did not observe under any conditions a decrease in peaks
corresponding to starting material or the appearance of a peak
for CMP (data not shown).
Unable to reconstitute any activity for SA222, we subjected
SA227 to a similar series of experiments. SA227 was incubated
with [14C]-4b and either CDP-ribitol or CDP-glycerol, and the re-
actions were analyzed by polyacrylamide gel electrophoresisChemistry & Biology(Figure 6A). In this case, [14C]-4b reacted to produce a higher
band in the presence of CDP-ribitol, but not in the presence of
CDP-glycerol. No slower-migrating band was visible in the
heat-treated control or in reactions containing [14C]-3b rather
than [14C]-4b. We also used [2-3H]-CDP-ribitol as a substrate
alongwith [14C]-4b in the SA227 reactions. The reactionmixtures
were spotted onto Whatman 3MM paper strips, and the strips
were developed by paper chromatography. Nonpolymeric start-
ing materials migrated up the strips, whereas polymeric product
remained at the origin. Scintillation counting showed that the
material at the origin was labeled with both 14C and 3H in a ratio
of >1:17 under the reaction conditions used, which confirms the
attachment of multiple [2-3H]-ribitol-5-phosphate units to the
[14C]-TarF product. Taken together, these results show that
SA227 transfers multiple RboP units to the disaccharide 4b,
which contains two GroP units, but not to the disaccharide 3b,
which contains one GroP unit.
We incubated the product of the SA227 reaction with SA222
and CDP-ribitol, but we did not detect any change in the length
of the polyRboP-WTA polymer, suggesting that SA222 does not
further extend this product.
The results reported above establish that SA227 is a ribitol-5-
phosphate polymerase that transfers ribitol-5-phosphate from
CDP-ribitol to compound 4 to form the (ribitol-5-phosphate)n-
(glycerol-3-phosphate)2-ManNAc-b-(1,4)-GlcNAc-pp-undecap-
renyl product 5 (Figure 2B). We have hence identified SA227 as
the polymerase TarL. We have also concluded that a ribitol-
5-phosphate primase is not required for the synthesis of poly-
RboP-WTA polymers inS. aureus, as it apparently is inB. subtilis
W23 (Lazarevic et al., 2002). The function of SA222, suggested
first to be a primase and later to be another polymerase, remains
to be established.
In Vitro Reconstitution of WTA Synthesis
Wecarried out a tandem reaction of TarA, TarB, TarF, and TarL to
produce WTA polymers in vitro from the GlcNAc-pp-lipid sub-
strate 1b. The synthetic WTA polymers formed in vitro wereFigure 3. HPLC and LC-MS Chromatograms of the TarA Enzymatic Reaction
(A and B) HPLC chromatograms after incubation of UDP-ManNAc with compound 1b and (A) heat-treated SA640 or (B) active enzyme.
(C and D) Retention times and intensities of the extracted product ions (m/z = 787.3) for (C) the authentic product, compound 2b, and (D) the product generated by
incubating UDP-ManNAc and compound 1b with SA640.
(E) The in vitro reaction catalyzed by SA640 (TarA); the experimental m/z value is shown (calculated m/z: 787.2819).15, 12–21, January 2008 ª2008 Elsevier Ltd All rights reserved 15
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tracted fromS. aureusNCTC8325 cells (Figure 6B). The synthetic
polymers could be stained with Alcian blue, an established
method for stainingWTAs. Themost abundant polymers synthe-
sized in vitro are 10 units smaller than the most abundant ex-
tracted WTAs, which have been estimated to contain 40 RboP
units (Ward, 1981). We were unable to significantly increase
the lengths of the WTA polymers produced in vitro by manipulat-
ing substrate ratios or enzyme concentrations. The molecular
basis for the control of polymer length is not known, but it is
evident from the distribution of polymeric products that TarL is
a processive enzyme. Additional factors may control polymer
lengths and product distributions in bacterial cells, explaining
the longer lengths of the natural WTA polymers. Whether WTA
polymer length is of any biological significance is not known.
DISCUSSION
Bacterial resistance to all main classes of antibiotics has devel-
oped. Most current antibiotics target a few essential bacterial
pathways, including DNA replication, cell wall biosynthesis, bac-
terial protein biosynthesis, and folate biosynthesis (Walsh and
Wright, 2005). It remains to be seen how many new inhibitors
can be developed to these well-studied pathways. There exists
a need to explore new targets. Virulence factors, which are in-16 Chemistry & Biology 15, 12–21, January 2008 ª2008 Elsevier Ltdvolved in the progression of disease in the host, but are not crit-
ical for the survival of the bacterium in vitro, are intriguing targets.
Virulence factors include toxins as well as factors important for
colonization and infection of host tissue (Marra, 2006). Recent
studies support the promise of small-molecule inhibitors of viru-
lence factors for treating bacterial infection (Hung et al., 2005).
S. aureus, one of the major nosocomial pathogens, is covered
in WTAs, anionic polymers that are attached to peptidoglycan
and that play a variety of important but poorly understood roles
in the biology of these and many other Gram-positive organisms
(Gotz, 2004). Recent experiments showed that deleting the first
gene in the WTA biosynthetic pathway, tarO, produces mutants
that are viable in vitro but are unable to colonize epithelial or
endothelial tissue (Weidenmaier et al., 2004, 2005). These studies
highlighted the essential role thatWTAsplay inS. aureus infection
and have prompted interest in understanding the WTA biosyn-
thetic pathway in more detail since it may be a target for
antibacterial agents. Brown and coworkers recently reported
that several genes downstream of tarO in the proposed S. aureus
biosynthetic pathway cannot be deleted (D’Elia et al., 2006), and
it was suggested that deletions of these genes may be lethal be-
cause toxic intermediates accumulate in the cell and/or because
a blockade in the WTA biosynthetic pathway diverts building
blocks, such as undecaprenyl phosphate, that would otherwise
be recycled and used in essential metabolic pathways such asFigure 4. HPLC Chromatograms and Radioactive Gel Analysis of TarB Enzymatic Reactions
(A–C) HPLC chromatograms after incubation of CDP-glycerol or CDP-ribitol after incubation with compound 2b and either heat-treated or untreated SA643. (A)
CDP-glycerol reaction with heat-treated enzyme. (B) CDP-glycerol reaction with active enzyme. (C) CDP-ribitol reaction with active enzyme.
(D) Autoradiogram of a polyacrylamide gel for reactions of compound 2b and SA643 in the presence of [14C]-CDP-glycerol. (+) and () symbols designate the
presence or absence, respectively, of the components indicated on the left; (D) indicates heat treatment. Lane 1, heat-treated enzyme reaction; lane 2, active
enzyme reaction; lane 3, authentic standard of [14C]-3b generated by using previously characterized B. subtilis TagB.
(E) The in vitro reaction catalyzed by TarB (SA643); the experimental m/z value is shown (calculated m/z: 941.2851).All rights reserved
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ruption of tar genes leads to a lethal phenotype increases interest
in theWTAbiosynthetic pathway as a target for intervention, but it
alsomakes it challenging to characterize the pathway in detail by
using a genetic approach. Therefore, we decided to establish the
functions of several of the genes proposed to be involved inWTA
biosynthesis via in vitro reconstitution of key intracellular steps.
We cloned, overexpressed, and purified eight S. aureus
NCTC8325 enzymes, tentatively identified as TarA, TarB, TarD,
TarF, TarI, TarJ, TarK, and TarL. Five of these enzymeswere pro-
posed to be involved in the conversion of compound 1 to com-
pound 5 via the linear sequence of steps shown in Figure 2A.
The other three, TarD, TarI, and TarJ (Badurina et al., 2003; Per-
eira and Brown, 2004), were cloned to enable the synthesis of
CDP-glycerol and CDP-ribitol in both radiolabeled and nonradio-
labeled forms. In addition, we synthesized via chemical methods
both UDP-ManNAc and compound 1b, which are the donor and
acceptor substrates, respectively, for TarA. The acceptor sub-
strate we prepared, compound 1b, differs from the natural sub-
strate in that it contains a farnesyl chain rather than the undecap-
renyl carrier lipid, but we have previously established that other
WTA biosynthetic enzymes are not very sensitive to the structure
of the attached lipid chain (Ginsberg et al., 2006; Zhang et al.,
2006). Therefore, there was precedent for the use of synthetic
alternative substrates in reconstituting the WTA biosynthetic
pathway of S. aureus.
Wewere able to reconstitute the activities of four of the five Tar
pathway enzymes proposed to be involved in the conversion of
compound 1 to compound 5. Although the four enzymes, TarA,
TarB, TarF, and TarL, operate on a membrane-anchored, unde-
caprenyl-containing substrate in cells, none of them are pre-
dicted to have membrane-spanning domains, and none require
the undecaprenyl substrate or a membrane interface for activity.
Kinetic studies have not been done, but the enzymes have rea-
sonable activity with the alternative substrate since all of the re-
actions largely went to completion in 2 hr. We were not able toChemistry & Biologyreconstitute the activity of the fifth putative Tar pathway enzyme,
the TarK/TarL homolog SA222; however, the work reported
here clearly shows that it is not required to form polyRboP-WTA
polymers.
Based on the results of the reconstitution experiments, we
have revised the S. aureus tar pathway in two ways. First, we
have altered the proposed function of TarF. This enzyme had
been thought to add two GroP units (D’Elia et al., 2006; Harring-
ton and Baddiley, 1985; Yokoyama et al., 1986), but we have
shown here that it adds only one. There may be several explana-
tions for the discrepancy between earlier results and the results
reported here. For example, the S. aureus strain that was origi-
nally analyzed to determine the structure of the linkage unit may
have been unusual in having a TarF that adds two GroP units. Al-
ternatively, the S. aureus strain we used as a source of genomic
DNA may be unusual in having a TarF that adds only one unit.
There may be an as yet undiscovered enzyme in this or other
S. aureus strains that adds a third GroP unit; if so, however, the
third GroP unit is not required for extension of the polyRboP
chain. Finally, it is possible that the original structural analyses
were incorrect. Analysis of polymers fractionated from complex
biologicalmixtures ismorecomplicated thananalysisof theprod-
ucts of an enzymatic reaction in vitro. At this point, we cannot dis-
tinguish among the possibilities. Therefore, we have revised the
function ofS. aureus TarF in Figure 2Bwith the caveat that gener-
ality has not yet been established for allS. aureus TarF homologs.
The other revision is more substantive. We have shown that
TarL, the poly(RboP) polymerase, can act directly on the TarF
product (compound 4), indicating that there is no need in
S. aureus for an RboP primase. The putative primase was thus
removed from the proposed pathway (compare Figures 2A and
2B). The function of SA222, a candidate for the primase encod-
ing a gene product that shows 88% end-to-end homology to
SA227, which we have identified as TarL, could not be estab-
lished from these in vitro experiments. However, all sequenced
S. aureus strains, which now number 12, contain a pair of genesFigure 5. Radioactive Gel Analysis of TarF Enzymatic Reactions
(A) Autoradiogram of a polyacrylamide gel for TarF-catalyzed reactions of [14C]-3b and either [14C]-CDP-glycerol or CDP-ribitol. (+) and () symbols designate the
presence or absence, respectively, of the components indicated on the left; (D) indicates heat treatment. Lane 1, heat-treated enzyme reaction containing [14C]-
CDP-glycerol; lane 2, active enzyme reaction containing [14C]-CDP-glycerol; lane 3, heat-treated enzyme reaction containing CDP-ribitol; lane 4, active enzyme
reaction containing CDP-ribitol.
(B) The in vitro reaction catalyzed by TarF (SA223); the experimental m/z value is shown (calculated m/z: 1095.2882).15, 12–21, January 2008 ª2008 Elsevier Ltd All rights reserved 17
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that the 222 gene is present in all 12 sequencedS. aureus strains,
it seems likely that it plays a role in WTA biosynthesis, although
that role does not appear to be essential (Bae et al., 2004). We
are currently trying to determine the function of SA222. In the
meantime, the reconstitution experiments described here lay
the groundwork for the discovery and characterization of WTA
inhibitors directed against key intracellular enzymes.
SIGNIFICANCE
Wall teichoic acids (WTAs) are virulence factors in Gram-
positive bacteria (Weidenmaier et al., 2004). Their involve-
ment in bacterial colonization and infection suggest that
WTA biosynthesis may be a target for therapeutic interven-
tion. Molecules that inhibit WTA biosynthesis could be
used to determinewhether targeting virulence factorswould
have efficacy as antibiotics. Using in vitro reconstitution of
enzymatic activity, we have delineated several intracellular
steps in the WTA biosynthetic pathway in S. aureus. To our
knowledge, this is the first biochemical study assigning
the function of gene products involved in the synthesis of
WTAs from a polyribitol-forming strain, and the work has
led to two corrections in the proposed biosynthetic
pathway in S. aureus. The reconstitution of the intracellularFigure 6. Analysis of TarL, SA227, Enzy-
matic Reactions
(A) Autoradiogram of a polyacrylamide gel for
TarL-catalyzed reactions of [14C]-4b or [14C]-3b
and either CDP-glycerol or CDP-ribitol. (+) and
() symbols designate the presence or absence,
respectively, of the components indicated on the
left; (D) indicates heat treatment. Only lane 3,
which contains [14C]-4b and CDP-ribitol in addi-
tion to active enzyme, shows the disappearance
of radiolabeled starting material and the formation
of a radiolabeled higher product.
(B) Polyacrylamide gel of WTAs stained with silver
and Alcian blue according to an established
method for detecting WTA polymers. Lane 1,
WTAs synthesized in vitro from UDP-ManNAc,
compound 1b, CDP-glycerol, and CDP-ribitol by
the tandem action of TarA, TarB, TarF, and TarL.
Lane 2, WTAs extracted from S. aureus
NCTC8325 cells.
(C) The in vitro reaction catalyzed by TarL (SA227).
steps of the WTA biosynthetic path-
way in a clinically relevant pathogen
paves the way for the discovery of in-
hibitors.
EXPERIMENTAL PROCEDURES
Reagents
Vectors, expression hosts, and His-Bind resin
were obtained from Novagen. Acrylamide
solutions were purchased from National Diagnos-
tics, TEMED was purchased from American
Bioanalytical, and TBE was purchased from Bio-18 Chemistry & Biology 15, 12–21, January 2008 ª2008 Elsevier LtdRad. All other enzymes, reagents, and buffers were obtained from Sigma-
Aldrich.
Cloning, Expression, and Purification of Putative Enzymes
The SAOUHSC_00640, SAOUHSC_00643, SAOUHSC_00223, SAOUHSC_
00222, SAOUHSC_00227, and tarD, tarI, and tarJ genes were PCR amplified
from Staphylococcus aureus NCTC8325 genomic DNA. The primer pairs
used for amplification are included in Table S1 (see the Supplemental Data
available with this article online). The PCR products were subcloned into
pET24b(+) (Novagen) at the XhoI and BamHI restriction sites for expression
in E. coli Rosetta2(DE3)pLysS (Novagen) as C-terminal hexa-His-tagged pro-
teins. The proteins were expressed in mid-log phase cultures after induction
with 0.5mMor 1mM IPTG for 4 hr at 37C, except for SA222 and SA227, which
were induced at 16C for overnight growth. Cells were lysed by freeze-thaw,
sonication, and French pressure at 16,000 lb/in2 in buffer supplemented with
rLysozyme and Benzonase (Novagen) and protease inhibitor cocktail (CalBio-
Chem). SA222 and SA227 lysis buffer was 50 mM HEPES (pH 7.0), 200 mM
NaCl, 0.5% CHAPS, 5% glycerol buffer. The remaining proteins were lysed
in 100 mM Tris-HCl (pH 7.5), 500 mM NaCl, 0.6% CHAPS, 0.5% Triton X-
100. Clarified lysate was purified by Ni2+-affinity chromatography (Novagen
His-Bind resin), yielding 5 mg/l TarA, 5 mg/l TarD, 1 mg/l TarB, 8 mg/l TarF,
7 mg/l TarI, 3 mg/l TarJ, 0.5 mg/l TarL, and 0.25 mg/l TarK as determined by
Lowry Assay. The proteins were stored as 20% and 50% glycerol stocks at
both 80C and 20C.
Preparation of UDP-ManNAc, [14C]-CDP-Glycerol,
Ribitol-5-Phosphate, and Compounds 1b, 2b, and 3b
UDP-ManNAc, compound 1b, and compound 2b were prepared as we previ-
ously described (Ginsberg et al., 2006). [14C]-CDP-glycerol was prepared asAll rights reserved
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phosphate was prepared as described previously (Bigham et al., 1984; Zolli
et al., 2001). Briefly, 0.1 g ribulose-5-phosphate was dissolved in water. After
the solution pH was confirmed to be above 7, sodium borohydride was added
to give a 1:1 molar ratio. Themixture was incubated at room temperature over-
night and was quenched with acetic acid (to pH 5), and NaOH was added to
adjust the pH to 8. The addition and removal by rotary evaporator of MeOH
was used to rid the resulting borate salts. The reaction products were analyzed
by Benedict’s Reagent to confirm the disappearance of ribulose-5-phosphate.
The reaction was purified by using Bio-Rad P2 gel. [14C]-radiolabeled com-
pound 3b was prepared by incubating TarB (500 nM) overnight with 10 mM
compound 2 and 30 mM [14C]-CDP-glycerol at room temperature in 20 mM
Tris-HCl (pH 7.5), 100 mM NaCl, and 10 mM MgCl2 buffer. The product,
[14C]-labeled 3b, was purified with a C18 column (Accubond SPE ODS-C18)
by washing with 100% water and eluting product with 100% ethanol.
Preparation of CDP-Ribitol and [2-3H]-CDP-Ribitol
Nonradiolabeled CDP-ribitol was prepared by incubating TarI overnight with 1
mM ribitol-5-phosphate and 2mMCTP in 50mMHEPES (pH 8), 10mMMgCl2,
1mMDTT, and 1U inorganic pyrophosphatase (Pereira and Brown, 2004). The
reaction wasmonitored by HPLC by using an anion-exchange column, Pheno-
sphere 5m SAX 250 3 4.6 mm, 5 mm (Phenomenex), to record the disappear-
ance of the CTP peak and production of a new peak (Buffer A: 5 mM
NH4H2PO4 [pH 2.8]; Buffer B: 750 mM NH4H2PO4 [pH 3.7]; linear gradient of
0%–20% solution B over 60 min, UV monitored at 271 nm). The identity of
CDP-ribitol was confirmed by mass spectroscopy. CDP-ribitol was used un-
purified in subsequent enzymatic reactions after spinning the reaction in
a 3000 MWCO filter to remove the enzyme. [2-3H]-radiolabeled CDP-ribitol
was prepared by extension of a previously outlined protocol to make [2-3H]-ri-
bitol-5-phosphate and CDP-ribitol (Landau et al., 1996; Pereira and Brown,
2004). A duplicate nonradiolabeled reaction was used to monitor the reaction
progress by analytical anion-exchange HPLC (Phenosphere 5m SAX 2503 4.6
mm, 5 mm [Phenomenex]). A 1:200 mixture of [2-3H]-D-glucose:D-glucose (2
mM total), 3 mM ATP, 4 mM NADP, 1.5 U glucose-6-phosphate dehydroge-
nase, 1 U hexokinase, 1 U 6-phosphogluconate dehydrogenase was incu-
bated at 30C in 100 mM triethanolamine buffer (pH 7.6), 10 mM MgCl2. After
3 hr, 1 mMZnCl2, 1 mMDTT, and TarJ were added. After an additional 4 hr, the
reaction was spun in a 3000MWCO filter to remove the enzymes. The resulting
ribitol-5-phosphate product was purified by using a previously established
method (Bartlett, 1959). Briefly, the reaction was applied to a 1 ml Dowex
13 8–400 anion-exchange resin (Cl form). The product was purified by using
a stepwise gradient of HCl and was found to elute with 0.02 N HCl. The pH of
the collected product was adjusted to 7 by using NaOH, and the solvent was
evaporated to concentrate the product. 1 U inorganic pyrophosphatase, 2 mM
CTP, and TarI were added to the purified ribitol-5-phosphate, and the reaction
was allowed to proceed for 1 hr at 30C in 100 mM triethanolamine buffer (pH
7.6), 10 mM MgCl2. The resulting [2-
3H]-CDP-ribitol was used in subsequent
enzymatic reactions.
HPLC Assay for TarA and TarB
TarA (500 nM) was incubated at room temperature for 2.5 hr with 50 mM
UDP-ManNAc and 100 mM compound 1b in buffer (20 mM Tris-HCl [pH 7.9],
500 mM NaCl). TarB (500 nM) was incubated at room temperature for 2.5 hr
with 50 mM CDP-glycerol or 50 mM CDP-ribitol and 100 mM compound 2b in
buffer (20 mM Tris-HCl [pH 7.5], 100 mM NaCl, 10 mM MgCl2). Reactions
were quenched with an equal volume of DMF, applied to an analytical anion-
exchange HPLC column (Phenosphere 5m SAX 2503 4.6 mm, 5 mm [Phenom-
enex]). TarA reactions were eluted by using a linear gradient of 0%–5% solu-
tion B over 30 min (buffer A: 5 mM NH4H2PO4 [pH 4.5]; buffer B: 750 mM
NH4H2PO4 [pH 3.7]). TarB reactions were eluted by using a linear gradient
from 0% solution B to 100% solution B over 25 min (buffer A: 5 mMNH4H2PO4
[pH 2.8]; buffer B: 750 mM NH4H2PO4 [pH 3.7]). UDP-ManNAc and UDP were
monitored at 260 nM. CDP-glycerol and CMP were monitored at 271 nM.
HPLC-MS and MS Assays
TarA and TarB reaction conditions were the same as described above, except
TarA reactions utilized 50 mM compound 2b and 150 mM compound 1b and
TarB reactions utilized 50 mM compound 3b and 200 mMCDP-glycerol. A totalChemistry & Biologyof 500 nM TarF was incubated with 50 mM compound 2b, 500 nM TarB, and
350 mM CDP-glycerol in buffer (20 mM Tris-HCl [pH 7.5], 100 mM NaCl, and
10 mM MgCl2). The products were purified by using a Phenomenex Strata
C18-E column by washing with 100% water and eluting product with 50:50
water:methanol. MS-TOF experiments were performed on a Waters mass
spectrometer. The purified compounds (TarA, TarB, and TarF products)
were run in negative ion mode by using water with 0.1% ammonium formate
as solvent. For ESI-MS analysis, mass spectra were acquired by using an Agi-
lent 1100 series LC/MSD mass spectrometer. After the mass of the purified
compound was obtained, unpurified TarA product and purified TagA product
(obtained as described previously [Ginsberg et al., 2006]) were subjected to
LC-MS analysis (extracted ion of 787.3 from the LC trace) by using a Zorbax
300SB-C18, 5 mm, 4.6 3 250 mm (Agilent) column. The compounds were
eluted at a flow rate of 0.5 ml/min by using a step gradient: 0%–60% solution
B for 8 min, 60%–100% solution B for 30 s, and 100% solution B for 7.5 min
(solution A, water, solution B, methanol, both solutions were supplemented
with 0.1% ammonium hydroxide as a solvent modifier).
TarB, TarF, TarK, and TarL Enzymatic Reactions for
Polyacrylamide Gel Electrophoresis Analysis
Reactions containing 1 mM purified compound 2b and 2 mM [14C]-CDP-glyc-
erol were incubated with TarB (500 nM). TarF reactions were performed by us-
ing 500 nM enzyme, 2 mMpurified [14C]-labeled compound 3b, and 4 mMeither
CDP-ribitol or [14C]-CDP-glycerol. TarK and TarL reactions were performed by
reacting 500 nM enzyme with 1 mM purified [14C]-labeled compound 4b or 1
mM purified [14C]-labeled compound 3b and 200 mM CDP-ribitol or CDP-glyc-
erol. TarB, TarF, TarK, and TarL enzymatic reactions were performed in buffer
containing 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 10 mM MgCl2. All en-
zymatic reactions were quenched with an equal volume of DMF after 2.5 hr.
[14C]-TagB product was obtained by using [14C]-CDP-glycerol and by follow-
ing our previously established method (Ginsberg et al., 2006).
Polyacrylamide Gel Electrophoresis Assay for TarB,
TarF, TarK, and TarL
The acrylamide gels used are similar to those described previously (Pollack
and Neuhaus, 1994). Bio-Rad minigels (7.0 cm 3 8.3 cm [H 3 W]; 1.0 mm
thickness) were constructed of 20% acrylamide/0.25 M TBE by mixing 4 ml
of a prepared acrylamide stock solution (Protogel, 30% [w/v] acrylamide:
0.8% [w/v] bisacrylamide), 0.25 ml water, 1.69 ml 103 TBE solution, 5 ml
TEMED, and 20 ml 10% ammonium persulfate. A total of 2 ml quenched enzy-
matic reactions were added to 2 ml 23 loading buffer consisting of 50% glyc-
erol and 0.1% bromophenol blue. The gels were electrophoresed in 0.25 M
TBE buffer running at a constant 100V for 107 min by using the Bio-Rad
Mini-PROTEAN system. The gels were dried between two sheets of cello-
phane, and the dried gels were exposed to a tritium storage phosphor screen
(GE Healthcare) for 48 hr. The screen was imaged by using a Typhoon 9400
imager and analyzed by using the ImageQuant TL computer software.
Paper Chromatography Assay to Determine
the Incorporation of RboP Repeats
Reactions (6 ml) containing 0.5 mMpurified compound 4b, 100 mM [2-3H]-CDP-
ribitol, and 500 nM TarL enzymewere incubated at room temperature for 2.5 hr
in 20 mM Tris base (pH 7.5), 10 mM MgCl2, and 100 mM NaCl. The reaction
was performed in triplicate. The reactions were quenched with 6 ml DMF and
3 ml spotted onto 3 MMWhatman paper in triplicate. The reactions were spot-
ted 3 cm from the bottom of the paper and were developed by using 5:3 iso-
butyric acid:1MNH4OH. The solvent was allowed to run to the top of the 20 cm
paper. The paper was dried, and the origin was cut out and placed in eppen-
dorf tubes. Water (750 ml) was added, and the tubes were placed at 100C for
4 hr. Heating samples allowed for a consistent amount of radioactive quench-
ing (10% for 14C and 20% for 3H). Ultima Gold scintillation cocktail (5 ml) was
added, and the samples were analyzed by using a scintillation counter.
WTA Polyacrylamide Gel Electrophoresis for TarL and Natural WTAs
A 150 ml reaction containing 1 mM purified compound 1b and 4 mMUDP-Man-
NAc was incubated at room temperature for 30min with 500 nM TarA in 20mM
Tris-HCl (pH 7.9) and 500 mM NaCl. 5 mM CDP-glycerol, 400 mM CDP-ribitol,
and 10 mM MgCl2 were added. Water (600 ml) was then added to dilute the15, 12–21, January 2008 ª2008 Elsevier Ltd All rights reserved 19
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stage enzymes, 500 nM each of TarB, TarF, and TarL were added, and the re-
action was allowed to proceed for an additional 2 hr at room temperature. The
reactions were quenched with 600 ml MeOH and evaporated by using a speed
vacuum. The reaction was resuspended in 15 ml 50:50 water:DMF and 120mM
NaOH (so as tomimic the final step inWTA isolation from cells in which the link-
age between ManNAc and GroP is cleaved). The reaction mixture was shaken
at room temperature for 15 min, and the reaction was loaded onto a 16 cm (1.0
mm thickness) polyacrylamide gel. For the separating gel, a 30% total acryl-
amide and 6% crosslinking solution was made by adding 340 mg Bisacryla-
mide to 30 ml Protogel solution. A total of 19.9 ml of this acrylamide solution
was added to 10 ml 3M Tris(HCl) (pH 8.5), 300 ml 10% ammonium persulfate,
and 30 ml TEMED. The stacking gel was prepared by mixing 1 ml Protogel
solution, 3 ml 3 M Tris(HCl) (pH 8.5), 6 ml water, 100 ml 10% ammonium per-
sulfate, and 10 ml TEMED. The running buffer consisted of 0.1 M Tris base
and 0.1 M Tricine (pH 8.1). A lane containing bromophenol blue was used as
a marker of gel progress. The gel was electrophoresed until the bromophenol
blue was 1 inch from the bottom. The gel was stained with Alcian blue and
silver staining as described previously (Wolters et al., 1990). Wild-type WTA
was a gift from Timothy Meredith.
Supplemental Data
Supplemental Data include a table listing the primer pairs used for PCR ampli-
fication and are available at http://www.chembiol.com/cgi/content/full/15/1/
12/DC1/.
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